STOCK TITAN

[SCHEDULE 13G/A] Praxis Precision Medicines, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Adage Capital Management and two principals report beneficial ownership of 2,374,085 shares of Praxis Precision Medicines, Inc. (PRAX), representing 11.28% of the 21,045,781 shares outstanding as of July 31, 2025. The filing is a Schedule 13G/A indicating the stake is held in the ordinary course of business and not to influence control. The reported holdings are held directly by Adage Capital Partners, L.P. and are disclosed by Adage Capital Management, L.P., Robert Atchinson and Phillip Gross, each showing shared voting and dispositive power over 2,374,085 shares and no sole voting or dispositive power. The filing cites the issuers principal executive office in Boston and uses the CUSIP 74006W207.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A prominent investment manager reports an 11.28% passive stake in PRAX, a sizable minority position that must be monitored by holders.

Adages disclosure shows a 2.37 million-share position held through affiliated partnerships with shared voting and dispositive power, consistent with institutional accumulation disclosed on a Schedule 13G/A for passive investors. The filing references 21,045,781 shares outstanding, providing a clear percentage basis. This level of ownership exceeds 5% and is material to shareholders because it represents a significant minority stake without stated intent to change control, as per the certification language. The structure identifies the reporting entities and individual principals, clarifying attribution of voting and disposition rights.

TL;DR: Adage and two named principals hold an 11.28% position with shared control indicators; filing signals passive intent under Schedule 13G/A.

The Schedule 13G/A classifies the position as held in the ordinary course of business and not for the purpose of influencing control, which is important for governance expectations. The disclosure names Adage Capital Management, L.P., and principals Robert Atchinson and Phillip Gross, and documents shared voting and dispositive power only. For boards and investors, a reported >10% stake is material for monitoring potential engagement but the form asserts passive intent, limiting immediate governance implications disclosed in this filing.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:09/02/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:09/02/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:09/02/2025

FAQ

How many Praxis (PRAX) shares does Adage Capital report owning?

The filing reports 2,374,085 shares beneficially owned.

What percentage of PRAX does the reported holding represent?

The reported position represents 11.28% of the class based on 21,045,781 shares outstanding as of July 31, 2025.

Which entities and individuals filed the Schedule 13G/A for PRAX?

The filing was made by Adage Capital Management, L.P. and disclosed by Robert Atchinson and Phillip Gross.

Does the Schedule 13G/A indicate intent to influence control of Praxis?

No. The certification states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Who has voting and dispositive power over the reported PRAX shares?

The filing shows 0 sole voting/dispositive power and 2,374,085 shared voting and shared dispositive power for each reporting person.
Praxis Precision Medicines, Inc.

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Latest SEC Filings

PRAX Stock Data

8.44B
26.12M
0.15%
113.11%
11.23%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON